Nurse Standing Orders for Buprenorphine Follow-Up Care in a Community Health Center Network

References

1. 1.↵
   1. Williams AR,
   2. Nunes EV,
   3. Bisaga A,
   4. Levin FR,
   5. Olfson M

   . Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse 2019;45(1):1–10.

   OpenUrl
2. 2.↵
   United States, Congress, House. Consolidated Appropriations Act, Section, 1262. Government Printing Office, 2023. 117^th Congress, 2^nd Session, House Report 2617. Available at: https://www.congress.gov/bill/117th-congress/house-bill/2617. Accessed 21 Apr. 2023.
3. 3.↵
   1. Alford DP,
   2. LaBelle CT,
   3. Kretsch N,
   4. et al

   . Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011;171(5):425–31.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. LaBelle CT,
   2. Han SC,
   3. Bergeron A,
   4. Samet JH

   . Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat 2016;60:6–13.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. LaBelle CT,
   2. Bergeron LP,
   3. Wason KW,
   4. Ventura AS

   . Clinical guidelines for the office based addiction treatment program for the use of buprenorphine and naltrexone formulations in the treatment of substance use disorders [Internet]. Boston Medical Center; 2018. Available from: https://www.bmcobat.org/resources/.
6. 6.↵
   1. Hernandez Y,
   2. Meyers-Ohki S,
   3. Farkas S,
   4. et al

   . How Massachusetts, Vermont, and New York are taking action to address the opioid epidemic. Am J Public Health 2018;108(12):1621–2.

   OpenUrl
7. 7.↵
   Opioid use disorder–medication assisted treatment: nurse care managers and scope of practice [Internet]. Washington state Department of Health, Nursing Care Quality Assurance Commission; 2019. Available from: https://www.doh.wa.gov/Portals/1/Documents/6000/NCAO16.pdf.
8. 8.↵
   CFR - Code of Federal Regulations Title 21. [Accessed 2021 Jan 24]; Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1306&showFR=1.
9. 9.↵
   1. Winograd RP,
   2. Presnall N,
   3. Stringfellow E,
   4. et al

   . The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse 2019;45(4):333–40.

   OpenUrl
10. 10.↵
    1. Jakubowski A,
    2. Fox A

    . Defining low-threshold buprenorphine treatment. J Addict Med 2020;14(2):95–8.

    OpenUrl
11. 11.↵
    1. Brooke J

    , Others. SUS-A quick and dirty usability scale. Usability evaluation in industry 1996;189(194):4–7.

    OpenUrl
12. 12.↵
    1. Bangor A,
    2. Kortum PT,
    3. Miller JT

    . An empirical evaluation of the system usability scale. International Journal of Human–Computer Interaction 2008;24(6):574–94.

    OpenUrlCrossRefWeb of Science
13. 13.↵
    1. Bangor A,
    2. Kortum P,
    3. Miller J

    . Determining what individual SUS scores mean: adding an adjective rating scale. J Usability Studies 2009;4(3):114–23.

    OpenUrl
14. 14.↵
    1. Flinter M,
    2. Hsu C,
    3. Cromp D,
    4. Ladden MD,
    5. Wagner EH

    . Registered nurses in primary care: emerging new roles and contributions to team-based care in high-performing practices. J Ambul Care Manage 2017;40(4):287–96.

    OpenUrl
15. 15.↵
    1. Wagner EH,
    2. Flinter M,
    3. Hsu C,
    4. et al

    . Effective team-based primary care: observations from innovative practices. BMC Fam Pract 2017;18(1):13.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. McLaughlin MF,
    2. Li R,
    3. Carrero ND,
    4. Bain PA,
    5. Chatterjee A

    . Opioid use disorder treatment for people experiencing homelessness: A scoping review. Drug Alcohol Depend 2021;224:108717.

    OpenUrl
17. 17.↵
    1. Weinstein LC,
    2. Iqbal Q,
    3. Cunningham A,
    4. et al

    . Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017–2018. Am J Public Health 2020;110(4):580–6.

    OpenUrl
18. 18.↵
    1. Biondi BE,
    2. Vander Wyk B,
    3. Schlossberg EF,
    4. Shaw A,
    5. Springer SA

    . Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract 2022;17(1):15.

    OpenUrl
19. 19.↵
    1. DeFlavio JR,
    2. Rolin SA,
    3. Nordstrom BR,
    4. Kazal LA Jr.

    Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Dupouy J,
    2. Palmaro A,
    3. Fatséas M,
    4. et al

    . Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. Ann Fam Med 2017;15(4):355–8.

    OpenUrlAbstract/FREE Full Text